# Junta clínica — PT-pseudo_dd011d696387 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_dd011d696387",
  "pid": "PT-pseudo_dd011d696387",
  "task": 1,
  "psa": 10.0,
  "age": 75,
  "months": 3,
  "pirads": "5",
  "psad": 0.372,
  "psav": 0.55,
  "psap": 14.0,
  "vol": 26.91,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8577571,
  "medhx": "Coronary artery disease, Benign prostatic hyperplasia",
  "meds": "atorvastatin, tamsulosin",
  "notes": "PSA 10 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 27 mL. csPCa 0.86.",
  "pmhx": [
    "Coronary artery disease",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "92 kg",
    "height": "179 cm",
    "bmi": "28.7",
    "bp": "101/75 mmHg",
    "hr": "73 bpm",
    "smoking": "Ex-smoker (13 pack-yr, quit 2002)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "11 Jan 2025",
  "enc_ref": "Dr. M. Jansen (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical attention sought for reassessment of a previously confirmed prostate malignancy alongside recent fluctuations in prostate-specific antigen levels."
    },
    {
      "s": "History",
      "t": "Clinical review initiated to reassess a previously established prostate cancer diagnosis. At 75 years of age, he works as an active dairy farmer and resides independently as a widower, relying on his adult daughter as his main point of contact. Body mass indexes 28.7 at a weight of 92 kg. Tobacco use ceased in 2002, accounting for a cumulative 13 pack-year exposure. Chronic coronary artery disease remains controlled via atorvastatin, while tamsulosin addresses benign prostatic hyperplasia; lower urinary tract symptoms are negligible, scoring just 2 on the IPSS scale. Daily life centers around agricultural work, with otherwise limited physical activity. Alcohol intake stays around three units weekly. Public transit limitations dictate a preference for morning visits. A decades-old meniscal injury occasionally flares during wet conditions, and he maintains routine cardiology appointments solely for blood pressure tracking. Unexplained weight reduction, skeletal discomfort, and blood in the urine are firmly denied, as he prioritizes continuing his agricultural schedule. December 2024 bloodwork revealed a prostate-specific antigen level of 10.0 ng/mL (free fraction 16%), complemented by unremarkable renal panels and complete blood counts. No medication sensitivities exist."
    },
    {
      "s": "Physical examination",
      "t": "Digital rectal examination proves normal; the prostate presents as symmetrically enlarged with a smooth, firm consistency and absent nodules or asymmetry. Hemodynamic parameters show a blood pressure of 101/75 mmHg and a pulse of 73 beats per minute. Systemic assessment identifies a well-nourished individual exhibiting no signs of acute distress; pulmonary fields are clear and cardiac rhythm remains regular."
    }
  ],
  "occupation": "active dairy farmer",
  "marital": "Widowed",
  "living": "Lives alone; adult daughter is primary contact",
  "next_of_kin": "None recorded — patient declines to nominate",
  "recent_other": [],
  "alcohol": "3 units / week",
  "exercise": "Sedentary lifestyle, occasional walking",
  "ipss": "IPSS score: 2/35 (mild LUTS)",
  "admin": "Patient prefers morning appointments (public transport).",
  "mri_hospital": "UMCG (Groningen)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_dd011d696387
Task: 1

Encounter: Urology - outpatient on 11 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 75-year-old male
  - PSA: 10.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.372 ng/mL²
  - PSA velocity: 0.55 ng/mL/yr
  - Prior PSA: 14.0 ng/mL
  - Prostate volume: 26.91 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8577571 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Coronary artery disease, Benign prostatic hyperplasia
  - Problem list / PMHx: Coronary artery disease, Benign prostatic hyperplasia
  - Current medication: atorvastatin, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 10 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 27 mL. csPCa 0.86.

Vitals: weight 92 kg, height 179 cm, BMI 28.7, BP 101/75 mmHg, HR 73 bpm. Smoking: Ex-smoker (13 pack-yr, quit 2002).

Chief complaint: Clinical attention sought for reassessment of a previously confirmed prostate malignancy alongside recent fluctuations in prostate-specific antigen levels.

History: Clinical review initiated to reassess a previously established prostate cancer diagnosis. At 75 years of age, he works as an active dairy farmer and resides independently as a widower, relying on his adult daughter as his main point of contact. Body mass indexes 28.7 at a weight of 92 kg. Tobacco use ceased in 2002, accounting for a cumulative 13 pack-year exposure. Chronic coronary artery disease remains controlled via atorvastatin, while tamsulosin addresses benign prostatic hyperplasia; lower urinary tract symptoms are negligible, scoring just 2 on the IPSS scale. Daily life centers around agricultural work, with otherwise limited physical activity. Alcohol intake stays around three units weekly. Public transit limitations dictate a preference for morning visits. A decades-old meniscal injury occasionally flares during wet conditions, and he maintains routine cardiology appointments solely for blood pressure tracking. Unexplained weight reduction, skeletal discomfort, and blood in the urine are firmly denied, as he prioritizes continuing his agricultural schedule. December 2024 bloodwork revealed a prostate-specific antigen level of 10.0 ng/mL (free fraction 16%), complemented by unremarkable renal panels and complete blood counts. No medication sensitivities exist.

Physical examination: Digital rectal examination proves normal; the prostate presents as symmetrically enlarged with a smooth, firm consistency and absent nodules or asymmetry. Hemodynamic parameters show a blood pressure of 101/75 mmHg and a pulse of 73 beats per minute. Systemic assessment identifies a well-nourished individual exhibiting no signs of acute distress; pulmonary fields are clear and cardiac rhythm remains regular.

Patient info: active dairy farmer; Widowed; Lives alone; adult daughter is primary contact.
Next of kin: None recorded — patient declines to nominate.

Lifestyle: alcohol 3 units / week; exercise Sedentary lifestyle, occasional walking; IPSS score: 2/35 (mild LUTS).


Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.63
  uncertainty  +/- 0.09 epistemic (95% band 0.47-0.80); among patients I cannot tell apart the outcome was 0.95 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.63: PI-RADS 5, PSA 10.0, PSAD 0.27, age 75, DRE Normal -> BIOPSY (clear). He wrote: "New(? -> no old MRI report included) PIRADS 5 and rising PSA makes biopsy necessary"
  2. distance 0.79: PI-RADS 5, PSA 9.3, PSAD 0.516, age 71, DRE Normal -> DEFER (clear). He wrote: "He has a ISUP3 cancer diagnosis already and he should be recommended treatment"
  3. distance 1.35: PI-RADS 5, PSA 13.5, PSAD 0.452, age 66, DRE Normal -> BIOPSY (clear). He wrote: "PIRADS 5 lesion in a man in active surveillance."

PRECEDENT: BIOPSY (weighted vote 0.65 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines address the management of patients with prostate cancer who have already undergone a biopsy. The guideline states that the decision to proceed with further biopsy or surveillance depends on the pathological findings from the prior biopsy and the clinical context. "The decision to proceed with further biopsy or surveillance should be based on the pathological findings from the prior biopsy and the clinical context."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not decisive because the guideline emphasizes the pathological findings from the prior biopsy, which are not detailed in the panel. Expert 4's tracing model suggests that the prior-biopsy status and DRE findings are important, but the guideline requires the pathological findings to be the basis for the decision, which are currently unknown.

WHAT WE STILL NEED
The guideline requires the pathological findings from the prior biopsy to guide the decision.
Prior biopsy status: Positive.
Grade of the prior biopsy: Unknown (not documented in the minute).
Number and dates of biopsy sessions: Unknown (not documented in the minute).
Whether he is on a surveillance protocol with a confirmatory biopsy due: Unknown (not documented in the minute).
The guideline requires the pathological findings from the prior biopsy to guide the decision.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges entirely on the pathological findings from the prior biopsy, as the EAU guideline requires them to guide the decision.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What was the prior biopsy result (Gleason/ISUP), number/dates of sessions, and surveillance plan?
  laboratory_results (get_lab_results) -> What are the full panel results, including free-PSA fraction, renal function, and haemoglobin?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the grade (Gleason or ISUP) of the prior biopsy?
  Q2. What is the number and dates of prior biopsy sessions?
  Q3. Is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
lesion size and zone: "discrete hypointense focus within the left peripheral zone at the base/mid-gland level, spanning roughly 14 mm"
extraprostatic extension: "not recorded"
comparison against an earlier study: "new"

psa_trend
serial PSA trend (rising, flat, or falling): "rising" (Values: 2.9 ng/mL on Nov 2023, 1.2 ng/mL on Mar 2024, 4.6 ng/mL on Jun 2024, 8.7 ng/mL on Sep 2024, 10.0 ng/mL on Jan 2025)

previous_notes
prior biopsy result (Gleason/ISUP), number/dates of sessions, and surveillance plan: "Urology consultation arranged to investigate the ongoing marker elevation alongside earlier positive biopsy results." (No specific Gleason/ISUP grade or number of sessions recorded)

laboratory_results
full panel results, including free-PSA fraction, renal function, and haemoglobin: "PSA: 10.0 ng/mL, Free PSA: 1.61 ng/mL, %Free PSA: 16%, Haemoglobin: 15.3 g/dL, Creatinine: 107 umol/L, eGFR: >60 mL/min/1.73m2"

WHAT I DID NOT OPEN
family-history anamnesis because the previous notes already mentioned prior biopsy results, which is the key missing piece for Q1, Q2, and Q3.

WHAT THIS SUPPORTS
findings that argue FOR sampling this patient now:
PI-RADS 5 lesion in the left peripheral zone measuring approximately 14 mm
PSA trend is rising

findings that argue AGAINST sampling this patient now:
prior biopsy status is positive (as indicated in the panel)

WHERE THIS LEANS
The documents confirm the need to ascertain the pathological findings from the prior biopsy to guide the next step, which is the core requirement of the EAU guideline.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 10.00 ng/mL over 5 points spanning 14 months; velocity +7.47 ng/mL per year; doubling time about 6 months.
PROJECTION at 6 months: 15.4 ng/mL, conformal 95% band 4.4-53.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.63
  uncertainty  +/- 0.10 epistemic (95% band 0.44-0.83), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.63  ('supports' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.63  ('supports' tier, fusion_full)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.65  (k=3 precedents)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.63 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('supports' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology report, PSA trend, previous notes, and laboratory results—do not answer the moderator's questions regarding the prior biopsy grade, the number/dates of sessions, or the surveillance plan.

ALIGNMENT WITH THE PANEL
The panel protocol concluded BIOPSY based on a weighted vote of experts, but this decision is explicitly contingent on the documented prior grade, which was not recorded in the retrieved documents.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the grade (Gleason or ISUP) of the prior biopsy? Not answered.
Q2. What is the number and dates of prior biopsy sessions? Not answered.
Q3. Is the patient currently on a surveillance protocol with a confirmatory biopsy due? Not answered.

WHAT CARRIES WEIGHT, AND WHY
The pathological findings from the prior biopsy are the most critical variable because the EAU guideline explicitly states the decision must be based on them. The rising PSA trend and the PI-RADS 5 lesion size are supportive but secondary to the required pathological context.

MY SUGGESTION TO THE CHAIR
Given that the required pathological data (Q1, Q2, Q3) is missing from the retrieved documents, the decision cannot be definitively made according to the guideline. Therefore, the case is not ready for a final decision.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Given the PI-RADS 5 finding and the rising PSA trend, coupled with the fact that the prior biopsy result grade was not documented, a new biopsy is indicated to establish the pathological context. The rising PSA trajectory, with a velocity of +7.47 ng/mL per year, supports the need for further tissue sampling. The evidence converged on the necessity of a biopsy to guide definitive management.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
